MedElevator Войти в исследования
← Поиск публикаций

DOI 10.4244/eij-d-23-00125

Медицинская библиотека · EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2023

P2Y12 inhibitor monotherapy versus dual antiplatelet therapy in patients with acute coronary syndromes undergoing coronary stenting: rationale and design of the NEOMINDSET Trial.

Guimarães Patricia O, Franken Marcelo, Tavares Caio A M, Silveira Fabio S, Antunes Murillo O, Bergo Ricardo R, Joaquim Rodrigo M, Hirai Jessica C S, Andrade Pedro B, Pitta Fabio G, Mariani José, Nascimento Bruno R, de Paula João E T, Silveira Marcos S, Costa Tiberio A O, Dall'Orto Frederico T C, Serpa Renato G, Sampaio Fernanda B A, Ohe Louis N, Mangione Fernanda M, Furtado Remo H M, Sarmento-Leite Rogerio, Monfardini Frederico, Assis Silvia R L, Nicolau José C, Sposito Andrei C, Lopes Renato D, Onuma Yoshinobu, Valgimigli Marco, Angiolillo Dominick J, Serruys Patrick W, Berwanger Otavio, Bacal Fernando, Lemos Pedro A

СтатьяПротокол клинического исследованияПеревод в очереди

Аннотация

Dual antiplatelet therapy (DAPT) is currently the standard of care after percutaneous coronary intervention (PCI). Recent studies suggest that reducing DAPT to 1-3 months followed by an aspirin-free single antiplatelet therapy (SAPT) strategy with a potent P2Y12 inhibitor is safe and associated with less bleeding. However, to date, no randomised trial has tested the impact of initiating SAPT immediately after PCI, particularly in patients with acute coronary syndromes (ACS). NEOMINDSET is a multicentre, randomised, open-label trial with a blinded outcome assessment designed to compare SAPT versus DAPT in 3,400 ACS patients undergoing PCI with the latest-generation drug-eluting stents (DES). After successful PCI and up to 4 days following hospital admission, patients are randomised to receive SAPT with a potent P2Y12 inhibitor (ticagrelor or prasugrel) or DAPT (aspirin plus a potent P2Y12 inhibitor) for 12 months. Aspirin is discontinued immediately after randomisation in the SAPT group. The choice between ticagrelor and prasugrel is at the investigator's discretion. The primary hypothesis is that SAPT will be non-inferior to DAPT with respect to the composite endpoint of all-cause mortality, stroke, myocardial infarction or urgent target vessel revascularisation, but superior to DAPT on rates of bleeding defined by Bleeding Academic Research Consortium 2, 3 or 5 criteria. NEOMINDSET is the first study that is specifically designed to test SAPT versus DAPT immediately following PCI with DES in ACS patients. This trial will provide important insights on the efficacy and safety of withdrawing aspirin in the early phase of ACS. (ClinicalTrials.gov: NCT04360720).

Для цитирования: Guimarães Patricia O, Franken Marcelo, Tavares Caio A M, Silveira Fabio S, Antunes Murillo O, Bergo Ricardo R, Joaquim Rodrigo M, Hirai Jessica C S, Andrade Pedro B, Pitta Fabio G, Mariani José, Nascimento Bruno R, de Paula João E T, Silveira Marcos S, Costa Tiberio A O, Dall'Orto Frederico T C, Serpa Renato G, Sampaio Fernanda B A, Ohe Louis N, Mangione Fernanda M, Furtado Remo H M, Sarmento-Leite Rogerio, Monfardini Frederico, Assis Silvia R L, Nicolau José C, Sposito Andrei C, Lopes Renato D, Onuma Yoshinobu, Valgimigli Marco, Angiolillo Dominick J, Serruys Patrick W, Berwanger Otavio, Bacal Fernando, Lemos Pedro A. P2Y12 inhibitor monotherapy versus dual antiplatelet therapy in patients with acute coronary syndromes undergoing coronary stenting: rationale and design of the NEOMINDSET Trial.. EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology. 2023. DOI: 10.4244/eij-d-23-00125.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.